Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study
- PMID: 25389255
- PMCID: PMC4366581
- DOI: 10.1093/cid/ciu871
Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study
Abstract
Background: The impact of early valve surgery (EVS) on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unresolved. The objective of this study was to evaluate the association between EVS, performed within the first 60 days of hospitalization, and outcome of SA PVIE within the International Collaboration on Endocarditis-Prospective Cohort Study.
Methods: Participants were enrolled between June 2000 and December 2006. Cox proportional hazards modeling that included surgery as a time-dependent covariate and propensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS and 1-year all-cause mortality on patients with definite left-sided S. aureus PVIE and no history of injection drug use.
Results: EVS was performed in 74 of the 168 (44.3%) patients. One-year mortality was significantly higher among patients with S. aureus PVIE than in patients with non-S. aureus PVIE (48.2% vs 32.9%; P = .003). Staphylococcus aureus PVIE patients who underwent EVS had a significantly lower 1-year mortality rate (33.8% vs 59.1%; P = .001). In multivariate, propensity-adjusted models, EVS was not associated with 1-year mortality (risk ratio, 0.67 [95% confidence interval, .39-1.15]; P = .15).
Conclusions: In this prospective, multinational cohort of patients with S. aureus PVIE, EVS was not associated with reduced 1-year mortality. The decision to pursue EVS should be individualized for each patient, based upon infection-specific characteristics rather than solely upon the microbiology of the infection causing PVIE.
Keywords: 1-year mortality; endocarditis; prosthetic valve; surgery.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Figures
Comment in
-
Editorial commentary: surgical therapy for Staphylococcus aureus prosthetic valve endocarditis: proceed with caution (Caveat Emptor).Clin Infect Dis. 2015 Mar 1;60(5):750-2. doi: 10.1093/cid/ciu877. Epub 2014 Nov 10. Clin Infect Dis. 2015. PMID: 25389250 No abstract available.
-
Reply to Biteker et al.Clin Infect Dis. 2015 May 15;60(10):1584-5. doi: 10.1093/cid/civ055. Epub 2015 Jan 30. Clin Infect Dis. 2015. PMID: 25637584 No abstract available.
-
Early surgery in prosthetic valve endocarditis: when and for whom?Clin Infect Dis. 2015 May 15;60(10):1584. doi: 10.1093/cid/civ052. Epub 2015 Jan 30. Clin Infect Dis. 2015. PMID: 25637589 No abstract available.
References
-
- Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA. 2007;297:1354–61. - PubMed
-
- Selton-Suty C, Célard M, Le Moing V, et al. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis. 2012;54:1230–9. - PubMed
-
- Wolff M, Witchitz S, Chastang C, Régnier B, Vachon F. Prosthetic valve endocarditis in the ICU: prognostic factors of overall survival in a series of 122 cases and consequences for treatment decisions. Chest. 1995;108:688–94. - PubMed
-
- Yu V, Fang G, Keys T, et al. Prosthetic valve endocarditis: superiority of surgical valve replacement versus medical therapy only. Ann Thorac Surg. 1994;58:1073–7. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical